Business Context and Reporting Period
Company: Legend Biotech Corporation (Legend Biotech)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2026
Business Overview: Legend Biotech is a global biopharmaceutical company focused on cell therapies for oncology. Its lead product, CARVYKTI (ciltacabtagene autoleucel), is a CAR-T cell therapy for multiple myeloma, developed in collaboration with Janssen Biotech, Inc. (Johnson & Johnson). The company has approximately 3,100 employees across the U.S., China, and Europe.
Key Financial Metrics
| Metric (in millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $305.1 | $195.0 |
| Net Loss | $(54.3) | $(101.0) |
| Operating Loss | $(49.8) | $(51.7) |
| Adjusted Net Loss (Non-IFRS) | $(10.5) | $(27.0) |
| Cash and Cash Equivalents | $646.4 | $441.7 |
| Total Liquidity (Cash + Time Deposits) | $834.6 | $N/A |
| Net Cash Used in Operating Activities | $(85.1) | $(103.6) |
| Collaboration Interest-Bearing Advanced Funding (Current Liability) | $266.0 | $319.1 |
Revenue Breakdown: Collaboration revenue was $298.4 million (driven by CARVYKTI sales), while License and other revenue was $6.7 million.
Cost Structure: Cost of collaboration revenue was $175.4 million. Research and development expenses were $85.7 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $110.1 million (56.5%) year-over-year, primarily due to a $112.8 million increase in collaboration revenue from CARVYKTI sales.
- Profitability Improvement: Net loss narrowed significantly from $101.0 million to $54.3 million. Operating loss improved slightly from $51.7 million to $49.8 million.
- Expense Management: R&D expenses decreased by $16.2 million due to the conclusion of patient dosing phases in major cilta-cel trials. However, Selling and distribution expenses increased by $9.1 million due to sales force expansion and marketing activities.
- Foreign Exchange Impact: Other expense, net, improved by $49.4 million, driven by a reduction in unrealized foreign currency exchange losses (from $55.2 million in Q1 2025 to $5.9 million in Q1 2026).
- Liquidity Position: Cash and cash equivalents decreased by $255.5 million during the quarter, largely due to investing activities (net addition to time deposits of $142.1 million and prepayments to collaborators).
Guidance, Outlook, and Risks
Outlook and Commentary:
- Management expects existing cash, time deposits ($834.6 million), and operating revenue to meet operational needs for at least the next 12 months.
- CARVYKTI net trade sales increased 62% year-over-year to approximately $597 million.
- The product is now available in 18 global markets following recent launches in Italy, Poland, the Czech Republic, and Australia.
- Subsequent Event: In April 2026, $55.0 million in milestone payments were triggered due to commercialization approvals in three major European countries. These will be recognized as revenue in Q2 2026.
Risks and Contingencies:
- Macroeconomic Factors: Risks include inflation, supply chain constraints, and potential future tariffs on pharmaceutical ingredients, though current U.S. tariffs exempt pharmaceuticals.
- Regulatory and Clinical: Uncertainties regarding clinical trial results, regulatory approvals, and patent litigation.
- Foreign Exchange: Significant exposure to RMB fluctuations against the U.S. dollar, which can cause volatility in reported earnings.
- Debt Repayment: The $266.0 million in collaboration interest-bearing advanced funding from Janssen is classified as a current liability, with Janssen expected to recoup the full amount within 12 months from pre-tax profits or milestone payments.
Key Facts for Investor Verification
- Revenue Recognition Timing: Verify the recognition of the $55.0 million milestone payment triggered in April 2026, expected in Q2 2026.
- Liquidity Runway: Confirm the company's assertion that $834.6 million in liquid assets is sufficient for 12+ months of operations given the $85.1 million quarterly operating cash burn.
- Debt Recoupment: Monitor the ability to repay the $266.0 million Janssen funding advance from collaboration profits within the next 12 months.
- Cost of Sales Trend: Analyze the sustainability of the gross margin as collaboration revenue grows, noting the $175.4 million cost of collaboration revenue in Q1 2026.
- Non-IFRS Metrics: Review the reconciliation of Adjusted Net Loss ($10.5 million) to Net Loss ($54.3 million) to understand the impact of non-cash items and foreign exchange.